The Academy of Medical Sciences has elected 11 University of Oxford biomedical and health scientists to its fellowship five of which are from the Nuffield Department of Medicine. All were selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.
Professor Adrian Hill, Director of the Jenner Institute becomes a Fellow for his leading role in the design and development of new vaccines for globally important infectious diseases over the course of over 25 years. He has demonstrated that non-replicating vectored vaccines, particularly simian adenoviruses used in heterologous prime-boost immunisation regimes, can protect safely through cellular as well as humoral immunity \u2013 supporting new vaccination approaches for malaria and Ebola.
Data from the national COVID-19 Infection Survey, which is led by senior NIHR Oxford BRC researcher Professor Sarah Walker, has revealed the impact of vaccination on antibody responses and new infections in a large group of adults from the general population. This major community surveillance survey, one of the NIHR\u2019s COVID-19 urgent public health studies, is a partnership between the University of Oxford, the Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC).
You are cordially invited to join the CCOUC Webinar on Health-EDRM Education and Research in China: Commemorating the 512 Wenchuan Earthquake. As a commemoration of the 512 Wenchuan Earthquake in 2008, experts will share with you an update on the latest Health-EDRM Education and Research in China. This is a webinar of the CCOUC 10th Anniversary International Webinar Series on Health Emergency and Disaster Risk Management.
Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival. From having no known effective drugs when the pandemic first erupted, patients are now offered treatments that have been robustly proven to reduce death and improve other outcomes, such as the length of hospital stay and the need for mechanical ventilation.
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.
Professor Cecilia Lindgren has been appointed as the new Director of the University of Oxford\u2019s Big Data Institute. Professor Lindgren will take up post on 1 April 2021. She succeeds Professor Gil McVean who was the founding director of the BDI, and Interim Director, Professor Martin Landray.
NDM's Professor Sarah Gilbert has been awarded the Royal Society for Arts\u2019 (RSA) Albert Medal for her work on the Oxford vaccine. Professor Gilbert is Professor of Vaccinology and the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world.
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world\u2019s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join and recruited to RECOVERY International. NDM's Peter Horby, Professor of Emerging Infectious Diseases and Global Health, and Joint Chief Investigator for the trial, said \u2018The RECOVERY trial has been an enormous success, enrolling over 36,000 patients and delivering clear results on six treatments already. By building on this success through international partnership we can speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies\".
Exscientia, the leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer\u2019s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer\u2019s disease (AD).
The Randomised Evaluation of COVID-19 Therapy (RECOVERY) has demonstrated that an anti-inflammatory treatment, tocilizumab, reduces the risk of death when given to hospitalised patients with severe COVID-19.
Early treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the University of Oxford have found.
The CRUK Oxford Centre is pleased to announce the appointment of Professor Tim Elliot as its new co-Director. Tim has recently joined the Nuffield Department of Medicine and Oriel College as the Kidani Professor of Immuno-Oncology. He re-joins the Oxford community from Southampton University, having previously completed his undergraduate degree in Biochemistry at Balliol and subsequently holding a Professorial post at the Weatherall Institute for Molecular Medicine.
Researchers from NDM's Big Data Institute working with Public Health England and NHS Test and Trace, have used Test and Trace data to find out why some individuals pass COVID-19 on to their contacts more easily than others, and if lateral flow tests are sufficient in detecting those who are most infectious
A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with \u00a32.5 million funding from UK Research and Innovation (UKRI).
Congratulations to Sir Dave Stuart, FRS FMedSci, NDM\u2019s Professor of Structural Biology, knighted for services to medical research and the scientific community.
The Nuffield Department of Medicine welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK.
Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand.
RECOVERY reports absence of a benefit from Azithromycin. The latest result from the NDM/NDPH RECOVERY trial shows the widely administered administration of a broad-spectrum antibiotic makes no difference to the routine outcome in hospitalised COVID19 disease. Results on other therapies are likely to follow in the coming weeks.
![\"The](\"https://www.ndm.ox.ac.uk/news/five-new-academy-of-medical-sciences-fellows-from-ndm/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n